1 in 4 Women are Non-Adherent with Oral Endocrine Therapy for Breast...
New results from the National Health and Wellness Survey show non-adherence is associated with greater work and activity impairment.(PRWeb June 02, 2014)Read the full story at http://www.prweb.com/releases/2014/06/prweb11900482.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 3, 2014 Category: Pharmaceuticals Source Type: news
Prediction of Late Disease Recurrence by H/I BiomarkerPrediction of Late Disease Recurrence by H/I Biomarker
A biomarker identifies ER-positive patients who are at risk for late disease recurrence after tamoxifen therapy, and those who would benefit from extended endocrine therapy with letrozole. Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 23, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Senior Bioinformatics Officer: Endocrinology, Institute of Cancer Research, London
Added via NatureJobs. The Institute of Cancer Research (ICR) is one of the world’s most influential cancer research institutes. The Endocrinology team, based in South Kensington, is focused on identifying phenotypic and genotypic alterations that influence response or resistance to endocrine therapy and translating these molecular findings into novel treatments.
They currently have a vacancy for a highly motivated Senior Bioinformatics Officer to provide support for ongoing molecular profiling and next-generation sequencing projects within the team, and to build on existing collaborations with other gro...
Source: Society for Endocrinology - July 23, 2013 Category: Endocrinology Source Type: news
Endocrine Treatments for Breast Cancer
Estrogen receptor-positive breast cancer can be treated with endocrine therapies, also called hormonal therapies. These drugs come in two classes: selective estrogen receptor modulators (SERMs)and aromatase inhibitors. These lower your estrogen levels, and may affect your fertility, as well as preventing a recurrence of breast cancer. Learn more about endocrine therapies for breast cancer. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - June 28, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Grand round: What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?
Source: J Clin Oncol
Area: News
The Grand Rounds series in the Journal of Clinical Oncology is designed to place original reports published in the journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches.
The subject of the latest grand round is endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer, which covers their efficacy, safety, treatment duration, and differences between aromatase inhibitors. (Source: NeLM - News)
Source: NeLM - News - January 31, 2013 Category: Drugs & Pharmacology Source Type: news
SIGN issues draft guidance on treatment of primary breast cancer
Source: SIGN
Area: News
SIGN has issued a draft guideline on the management of primary breast cancer. This draft provides recommendations on the treatment of patients with operable early breast cancer. It includes recommendations on surgery, chemotherapy, radiotherapy, endocrine therapy and others, e.g. biological therapy.
Management of patients with metastatic disease is not covered in this guideline.
Please see link for details. (Source: NeLM - News)
Source: NeLM - News - January 22, 2013 Category: Drugs & Pharmacology Source Type: news
